Cullinan Oncology Inc Pearl Clinical Update Call Transcript
Hello. Welcome to the Cullinan Pearl Clinical Update Webinar hosted by Cullinan Oncology. Please be aware that this call is being recorded.
I'm Juliet Labadorf with Investor Relations here at Cullinan, and I'm pleased to introduce today's call, which will focus on the ongoing Phase I/IIa clinical trial evaluating CLN-081 in non-small cell lung cancer patients, EGFR, or epidermal growth factor receptor, exon 20 insertion mutation. The data sets presented are available as a poster presentation in the 2021 American Society of Clinical Oncology's Annual Meeting.
Before we proceed, we may be making certain forward-looking statements during this program. This may include statements regarding our preclinical and clinical development plans, clinical trial design, the strategy of our product candidates, among other topics. We encourage you to review our forward-looking statements in the slide deck which will be accessible on our website subsequent to the call.
Providing prepared remarks on the call today will be Owen Hughes, Cullinan's Chief Executive Officer; Jon Wigginton,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |